報(bào) 告 內(nèi) 容 簡 介 |
報(bào)告人簡介：Dr. Pornchai Rojsitthisak serves as the Director of the Center of Excellence in Natural Products for Ageing and Chronic Diseases and holds a faculty appointment in the Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University. He earned his Ph.D. in Pharmaceutical Sciences from the University of Southern California. Dr. Rojsitthisak’s research expertise lies in natural product-based drug discovery and development, with a particular focus on improving the physicochemical and biopharmaceutical properties of drug candidates. His work integrates in silico drug screening, prodrug design, polymer-drug conjugation, and nanoformulation strategies. He has led the development of innovative curcumin nanoparticle formulations and curcumin-derived prodrugs, supported by extensive in vitro and in vivo evaluations. Dr. Rojsitthisak has authored numerous scientific publications contributing significantly to the advancement of pharmaceutical sciences and translational drug research. 報(bào)告內(nèi)容簡介： This presentation showcases the integrated approach to drug discovery at the Center of Excellence in Natural Products for Ageing and Chronic Diseases, Faculty of Pharmaceutical Sciences, Chulalongkorn University. Beginning with traditional methods rooted in natural products, the research highlights the systematic development of an extract from Dendrobium formosum, a Thai orchid species, for osteoarthritis treatment. Key bioactive compounds were identified, and their anti-inflammatory activity was confirmed through in vitro and in vivo evaluations.Building upon this foundation in ethnopharmacology, the presentation transitions into modern drug discovery using artificial intelligence. The second segment features the application of the RUSH cloud-based platform for virtual screening of CXCR4 inhibitors, targeting cancer metastasis. Deep learning models were used to prioritize compounds, followed by in vitro validation, identifying CU-04 as a promising lead. By moving from traditional natural products to AI-accelerated drug screening, this presentation illustrates how the Center strategically combines heritage knowledge with modern tools to address ageing and chronic diseases. The collaborative model, including partnerships such as the China-Thailand Joint Laboratory with Taizhou University, positions the Center as a leader in innovation-driven drug discovery. |
浙公網(wǎng)安備 33100202001351號
